Difference in serum miRNA expression between immunoglobulin‑sensitive and ‑insensitive incomplete Kawasaki disease patients

Wang, Yan; Li, Chunli; Niu, Ling; Fu, Mingyu; Tian, Jing; An, Xinjiang

doi:10.3892/etm.2020.9593

“…Inclusion criteria: meeting the diagnostic criteria for Ig-insensitive KD [ 15 ], ≤10 years old, normal cognitive and communication skills, no history of drug allergy, and no medication that may affect the results of this study within the past six months.…”

Section: Methodsmentioning

confidence: 99%

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease

Ma

¹

,

Zhang

²

,

Fan

³

2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

This study mainly analyzes the clinical effect of glucocorticoid (GC) plus intravenous immunoglobulin (IVIG) in treating children with immunoglobulin (Ig)-insensitive Kawasaki disease (KD). From September 2013 to November 2021, 86 Ig-insensitive KD children were selected, including 46 children (observation group, Obs) treated with GC plus IVIG, and 40 children (control group, Con) treated with IVIG. The symptom (fever and fever) resolution time, inflammatory factors (C-reactive protein, CRP; procalcitonin, PCT; interleukin-6, IL-6), immune indicators (CD3+, CD4+, CD8+ T lymphocytes CD3+, CD4+, and CD4+/CD8+), and incidence of adverse reactions were compared between the groups. The results identified shorter fever and rash resolution time in Obs compared with Con. The posttreatment CRP, PCT, IL-6, and CD8+ and the incidence of adverse events reduced notably in Obs and were lower than Con, while CD3+, CD4+, and CD4+/CD8+ elevated statistically and were higher than that of Con. Our results indicate that GC plus IVIG can significantly promote symptom resolution, alleviate inflammatory response, and improve immune function in children with Ig-insensitivity KD, with favorable safety and clinical promotion value.

show abstract

“…reported that the level of miRNA-199b-5p decreased while miR-145 and miR-155 concentrations increased in the IVIG-insensitive group compared to the IVIG-sensitive group. These results suggest that miR-145, miR-155 and miR-199b-5p could be a potential indicator for IVIG ( 116 ). A study involves of 80 healthy controls and 102 KD patients focusing on the level of miR-200c and miR-371-5p revealed that miR-200c was found to play a crucial role in the endothelial cell apoptosis process and the anti-inflammation response of the vascular muscle cells ( 117 ), indicating the potential of miR-200c in regulating CADs ( 118 ).…”

Section: The Role Of Mirna In the Clinical Application Of Kawasaki Di...mentioning

confidence: 74%

MicroRNAs in Kawasaki disease: An update on diagnosis, therapy and monitoring

Xiong

¹

,

Xu

²

,

Zhang

³

et al. 2022

View full text Add to dashboard Cite

Kawasaki disease (KD) is an acute autoimmune vascular disease featured with a long stage of febrile. It predominantly afflicts children under 5 years old and causes an increased risk of cardiovascular combinations. The onset and progression of KD are impacted by many aspects, including genetic susceptibility, infection, and immunity. In recent years, many studies revealed that miRNAs, a novel class of small non-coding RNAs, may play an indispensable role in the development of KD via differential expression and participation in the central pathogenesis of KD comprise of the modulation of immunity, inflammatory response and vascular dysregulation. Although specific diagnose criteria remains unclear up to date, accumulating clinical evidence indicated that miRNAs, as small molecules, could serve as potential diagnostic biomarkers and exhibit extraordinary specificity and sensitivity. Besides, miRNAs have gained attention in affecting therapies for Kawasaki disease and providing new insights into personalized treatment. Through consanguineous coordination with classical therapies, miRNAs could overcome the inevitable drug-resistance and poor prognosis problem in a novel point of view. In this review, we systematically reviewed the existing literature and summarized those findings to analyze the latest mechanism to explore the role of miRNAs in the treatment of KD from basic and clinical aspects retrospectively. Our discussion helps to better understand the pathogenesis of KD and may offer profound inspiration on KD diagnosis, treatment, and prognosis.

show abstract

“…Additionally, IVIg is thought to interfere 7 Oxidative Medicine and Cellular Longevity with the passage of autoimmune cells across the bloodnerve barrier and to reduce antibody production by B cells, interfere with B cell proliferation through cell surface receptors, block the activity of certain B cell subtypes, interrupt several steps in the complement activation cascade, and affect activity mediated by the Fc receptor [31,34]. The correlations between IVIg treatment effectiveness and miRNA level were described in many studies in different clinical situations [35][36][37][38]. IVIg replacement therapy in different immunodeficiency patients is thought to be able to modulate miRNA level.…”

Section: Discussionmentioning

confidence: 99%

miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy

Dziadkowiak

¹

,

Baczyńska

²

,

Wieczorek

³

et al. 2023

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Background. MicroRNAs are endogenous, small noncoding RNA molecules that play a pivotal role in the regulation of gene expression. MicroRNAs are involved in many biological processes such as proliferation, cell differentiation, neovascularization, and apoptosis. Studies on microRNA expression may contribute to a better understanding of the pathomechanism of chronic inflammatory demyelinating polyneuropathy (CIDP) and consequently enable the development of new therapeutic measures using antisense miRNAs (antagomirs). In this study, we evaluated the level of miR-31-5p in the serum of patients with CIDP and its correlation with the miR-31-5p level and clinical presentation and electrophysiological and biochemical parameters. Methods. The study group consisted of 48 patients, mean age 61.60 ± 11.76 , who fulfilled the diagnostic criteria of a typical variant of CIDP. The expression of miR-31-5p in patient serum probes was investigated by droplet digital PCR. The results were correlated with neurophysiological findings and the patient’s clinical and biochemical parameters. Results. The mean copy number of miRNA-31 in 100 μl serum was 1288.64 ± 2001.02 in the CIDP group of patients, while in the control group, it was 3743.09 ± 4026.90 . There was a significant positive correlation (0.426) between IgIV treatment duration and miR-31-5p expression. Patients without IgIV treatment showed significantly lower levels of miR-31 compared to the treated group ( 259.44 ± 304.02 vs. 1559.48 ± 2168.45 ; p = 0.002 ). The group of patients with body weight > 80 kg showed statistically significantly lower levels of miRNA-31-5p than the patients with lower body weight ( 934.37 ± 1739.66 vs. 1784.62 ± 2271.62 , respectively; p = 0.014 ). Similarly, the patients with elevated cerebrospinal fluid (CSF) protein levels had significantly higher miRNA-31-5p expression than those with normal protein levels ( 1393.93 ± 1932.27 vs. 987.38 ± 2364.10 , respectively; p = 0.044 ). Conclusion. The results may support the hypothesis that miR-31-5p is strongly involved in the autoimmune process in CIDP. The positive correlation between higher miR-31-5p levels and duration of IVIg treatment may be an additional factor explaining the efficacy of prolonged IVIg therapy in CIDP.

show abstract

Difference in serum miRNA expression between immunoglobulin‑sensitive and ‑insensitive incomplete Kawasaki disease patients

Cited by 3 publications

References 21 publications

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease

MicroRNAs in Kawasaki disease: An update on diagnosis, therapy and monitoring

miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy

Contact Info

Product

Resources

About